We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Metastatic Breast Cancer
Center of Excellence
Interested in receiving weekly updates about the Metastatic Breast Cancer Center of Excellence?
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Chemotherapy should be recommended. The benefit and potential hazard should be fully discussed with the patient, based on her high Ki67, LVI, relatively young age. Besides, information related to tumor grade and menopausal status should be provided for detailed discussion.
giovanni marini
Nov 01, 2020
chemioterapia seguita da ormonoterapia (Google translate: chemotherapy followed by hormonal therapy)
Kendra Dean
Nov 02, 2020
Chemo due to age, male and Ki67
neil lins
Nov 06, 2020
QT + HT
Raphael Catane
Nov 06, 2020
Why performing Oncotype, if you don't follow its recommendation.
Serkan Akin
Nov 06, 2020
Ki67 of final path report should be considered. Oncotype score could also be reliable in males. However I think the most necessary issue should be to check BRCA and other germline mutations in this guy. Eventually I want to start him tamoxifen for 5 years with close follow-up
JULIO CESAR VELASCO RODRIGUEZ
Nov 07, 2020
oncotype in male breast cancer is rarely used, but it serves to avoid over-treating patients, experience is limited, but would only indicate hormonal therapy based on the oncotype score
Sewa Legha
Nov 07, 2020
Male Breast Cancer is highly sensitive to Hormonal therapy. So it is generally the preferred first option of treatment.
In addition to endocrine therapy, a case can be made to adding chemotherapy to high risk patients(such as those with Lymph node metastases.
Since this patient has node negative disease, I would not recommend any chemotherapy. Instead use endocrine therapy such as Tamoxifen for a duration of 5 years.
Sewa S. Legha, MD
Del Barco Sonia
Nov 09, 2020
First, if you do oncotype .. you follow it or not?
Second, in case of woman i choose chemo because age and therefore in this case, the same
Ludwing Bacon Fonseca
Dec 11, 2020
If I send a Genomic profile.... I should follow the recommendation.... so my personal opinion with all information is : Tamoxifen x 5a
Apr 18, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Ana
C.
Sandoval Leon
MD
mehrdad payadeh
Oct 31, 2020
Bogdan Cristian Dinu
Oct 31, 2020
luis betancourt
Oct 31, 2020
[email protected] [email protected]
Nov 01, 2020
giovanni marini
Nov 01, 2020
Kendra Dean
Nov 02, 2020
neil lins
Nov 06, 2020
Raphael Catane
Nov 06, 2020
Serkan Akin
Nov 06, 2020
JULIO CESAR VELASCO RODRIGUEZ
Nov 07, 2020
Sewa Legha
Nov 07, 2020
Del Barco Sonia
Nov 09, 2020
Ludwing Bacon Fonseca
Dec 11, 2020
Apr 18, 2024
Pending Moderator approval.